FDA expands use of kidney cancer drug belzutifan

Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier-stage kidney cancers in combination with an immunotherapy drug.

This move marks the latest expansion of belzutifan's indications after it was originally approved in 2021. ...